相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper
Graeme C. Young et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)
Opportunities for Accelerating Drug Discovery and Development by Using Engineered Drug-Metabolizing Enzymes
Elizabeth M. J. Gillam et al.
DRUG METABOLISM AND DISPOSITION (2023)
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal
Vasileios-Periklis Stamatellos et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator
Sekhar Surapaneni et al.
DRUG METABOLISM AND DISPOSITION (2021)
Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial
John Sharretts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Hypnotic effect of thalidomide is independent of teratogenic ubiquitin/proteasome pathway
Yuki Hirose et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study
Douglas K. Spracklin et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the Metabolites in Safety Testing Regulatory Guidance
Simone Schadt et al.
DRUG METABOLISM AND DISPOSITION (2018)
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2018)
A decade of drug metabolite safety testing: industry and regulatory shared learning
Debra Luffer-Atlas et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database
Thomas M. Monticello et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Implications for Metabolite Quantification by Mass Spectrometry in the Absence of Authentic Standards
Panos Hatsis et al.
DRUG METABOLISM AND DISPOSITION (2017)
Practical Applications of NMR Spectroscopy in Preclinical Drug Metabolism Studies
Raman Sharma et al.
EMAGRES (2015)
Novel Mechanism for Valproate-Induced Teratogenicity
Kristin Fathe et al.
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY (2014)
Software automation tools for increased throughput metabolic soft-spot identification in early drug discovery
Veronica Zelesky et al.
BIOANALYSIS (2013)
Which Metabolites Circulate?
Cho-Ming Loi et al.
DRUG METABOLISM AND DISPOSITION (2013)
The early estimation of circulating drug metabolites in humans
Debra Luffer-Atlas
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Use of relative 12C/14C isotope ratios to estimate metabolite concentrations in the absence of authentic standards
Filip Cuyckens et al.
BIOANALYSIS (2012)
Teratogenic effects of thalidomide: molecular mechanisms
Takumi Ito et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR
Gregory S. Walker et al.
DRUG METABOLISM AND DISPOSITION (2011)
Drug Metabolite Profiling and Identification by High-resolution Mass Spectrometry
Mingshe Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Drug-Induced QTC Prolongation Dangerously Underestimates Proarrhythmic Potential: Lessons From Terfenadine
Luc M. Hondeghem et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Determination of Exposure Multiples of Human Metabolites for MIST Assessment in Preclinical Safety Species without Using Reference Standards or Radiolabeled Compounds
Shuguang Ma et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2010)
Tegaserod and the Risk of Cardiovascular Ischemic Events: An Observational Cohort Study
Jeanne Loughlin et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations
Ping Yi et al.
BIOANALYSIS (2010)
Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications
Sharon Diamond et al.
DRUG METABOLISM AND DISPOSITION (2010)
Interpretation and Considerations on the Safety Evaluation of Human Drug Metabolites
Aisar H. Atrakchi
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction
Jonathon N. Bauman et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Predicting Circulating Human Metabolites: How Good Are We?
Shelby Anderson et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Approaches to the Assessment of Stable and Chemically Reactive Drug Metabolites in Early Clinical Trials
Thomas A. Baillie
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment
Dennis A. Smith et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding
Shintaro Nakayama et al.
DRUG METABOLISM AND DISPOSITION (2009)
Metabolites in safety testing
Timothy W. Robison et al.
BIOANALYSIS (2009)
Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma
G. J. Dear et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection
ChungPing Yu et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2007)
Metabolites and safety: What are the concerns, and how should we address them?
Dennis A. Smith et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2006)
Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites
Thomayant Prueksaritanont et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2006)
Safety assessment of drug metabolites: Characterization of chemically stable metabolites
W. Griffith Humphreys et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2006)
A regulatory perspective on issues and approaches in characterizing human metabolites
Karen L. Davis-Bruno et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2006)
Thalidomide metabolism and hydrolysis: Mechanisms and implications
Erin R. Leppert et al.
CURRENT DRUG METABOLISM (2006)
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai et al.
NATURE REVIEWS CANCER (2006)
Is declining innovation in the pharmaceutical industry a myth?
EF Schmid et al.
DRUG DISCOVERY TODAY (2005)
Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development
DC Evans et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2004)
Risk of drug-induced congenital defects
M De Santis et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2004)
Letter to the Editor - Reply
TA Baillie et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2003)
Letter to the Editor
KL Hastings et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2003)
Drug metabolites in safety testing
TA Baillie et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2002)
Cerivastatin and reports of fatal rhabdomyolysis.
JA Staffa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Concordance of the toxicity of pharmaceuticals in humans and in animals
H Olson et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2000)
分享论文
